Le Lézard
Classified in: Health, Science and technology
Subject: CCA

Accuray to Report Third Quarter Fiscal 2024 Financial Results on May 1, 2024


MADISON, Wis., April 17, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2024, ended March 31, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on May 1, 2024.

The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is (877) 344-7529 (USA) or (412) 317-0088 (international), conference ID: 2071766.

A live webcast of the call will also be available from the Investor Relations section of the company's website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available until Accuray announces its results for the fourth quarter of fiscal 2024.

About Accuray
Accuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases?while making commonly treatable cases even easier?to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.

Investor Contact
Aman Patel, CFA
Investor Relations, ICR-Westwicke
+1 (443) 450-4191
[email protected]

Media Contact
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
[email protected] 

 

SOURCE Accuray Incorporated


These press releases may also interest you

at 09:25
Aptorum Group Limited ("Aptorum Group" or "We"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year...

at 09:20
Heidelberg Engineering welcomes ARVO delegates to experience Heidelberg image quality across a wide range of applications from basic vision research to clinical trials and guided therapy, all with the goal of improving patient care. See how these...

at 09:20
ImmunoTek Plasma is hosting a ribbon cutting and open house to give people in the Jefferson City area the chance to tour the state-of-the-art facility and learn more about the need for blood-plasma donations. Monday, May 6, 2024 9:00 a.m. ? 11:00...

at 09:20
Emtora Biosciences, Inc., a privately-held, San Antonio-based biotechnology company developing a novel reformulated version of a previously-approved drug today announced the acceptance of an abstract for oral presentation at the upcoming Digestive...

at 09:15
LivaNova PLC , a market-leading medical technology company, today announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024. In this newly created position, Tezel will leverage his career of more...

at 09:15
Renovion Inc., a biopharmaceutical company focused on developing therapies to restore lung health in individuals with mucus-related lung diseases, announced topline results of the Phase 2 CLIMB study of ARINA-1 in individuals with non-CF...



News published on and distributed by: